ABSTRACT: Pregnant women with rheumatologic disease face dilemmas created by their pregnancy and are at increased risk for compli-cations.Some dilemmas are created by the medications that areused to control inflammation; others are created by disease activityor laboratory values.Dilemmas include fetal risk from receivingleflunomide and exposure to tumor necrosis factor Āin pregnancy;timing and management of lupus nephritis in pregnancy; andasymptomatic elevated antiphospholipid antibodies.(J MusculoskelMed.2008;25:190-195).

Should women discontinue medications for rheumatoid arthritis (RA) when pregnant? Should they become pregnant with previous lupus nephritis? Should they risk miscarriage with positive anti-phospholipid (aPL) antibodies?

Pregnant women with rheumatologic disease often face dilemmas created by their pregnancy and are at increased risk for both pregnancy- and disease-related complications. In this article, I present several cases of women who had a rheumatologic disease and were pregnant or wanted to be and offer advice and recommendations for addressing their dilemmas.

Dilemma 1: Pregnancy in a woman receiving leflunomide(Drug information on leflunomide) and etanercept(Drug information on etanercept) for RA
A 28-year-old white woman with a 5-year history of RA calls on a Monday morning because she dis-covered that she is pregnant,probably about 8 weeks gestation, based on her last menstrual period. She has been taking leflunomide, 20 mg/d, plus etanercept, 50 mg/wk, for the past 2 years and has been doing well on this regimen. She asks whether she should continue her medications and, if she does, what effect they will have on her baby.

Comments. Any woman of reproductive age should be instructed not to become pregnant while taking leflunomide or methotrexate(Drug information on methotrexate) (MTX). Both medications are FDA category X (Table 1), meaning that the high potential of harm to the developing fetus outweighs any potential benefit of the drug to the mother. Leflunomide inhibits purine metabolism, interfering with DNA formation and leading to chromosome abnormalities and cell death. MTX is a dihydrofolate reductase inhibitor that decreases maternal folic acid(Drug information on folic acid) reserves; having low folic acid levels early in pregnancy increases the risk of neural tube defects.

With first trimester exposure, in particular, the effects of leflunomide and MTX can be devastating to a fetus.The most common birth defects among women exposed to these medications are abnormalities in the CNS, limbs, and palate, as well as cranial ossification.¹ MTX often is used to abort ectopic pregnancies but in doses several times higher than typically used to manage rheumatologic disease.